Curanex Pharmaceuticals (CURX) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Curanex Pharmaceuticals (CURX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||
Research And Development | 2.26M (-2.16%) | 2.31M (+239.71%) | 680K | - | - | - | - | - | - |
Selling General And Administrative | 930K (+19.23%) | 780K (+188.89%) | 270K (+350.00%) | 60K (-57.14%) | 140K (-6.67%) | 150K (+66.67%) | 90K (+125.00%) | 40K | - |
Operating Expenses | 3.18M (+2.91%) | 3.09M (+225.26%) | 950K (+1483.33%) | 60K (-57.14%) | 140K (-39.13%) | 230K (+155.56%) | 90K (+125.00%) | 40K | - |
Operating Income | |||||||||
Operating Income | -3.18M (+2.91%) | -3.09M (+225.26%) | -950.00K (+1483.33%) | -60.00K (-57.14%) | -140.00K (-39.13%) | -230.00K (+155.56%) | -90.00K (+125.00%) | -40.00K | - |
Ebit | -3.18M (+2.91%) | -3.09M (+225.26%) | -950.00K (+1483.33%) | -60.00K (-57.14%) | -140.00K (-6.67%) | -150.00K (+66.67%) | -90.00K (+125.00%) | -40.00K (-50.00%) | -80.00K |
EBITDA | -3.15M (+2.61%) | -3.07M (+223.16%) | -950.00K (+1483.33%) | -60.00K (-57.14%) | -140.00K (-6.67%) | -150.00K (+66.67%) | -90.00K (+125.00%) | -40.00K (-50.00%) | -80.00K |
Net Income | |||||||||
Net Income From Continuing Operations | -3.15M (+2.61%) | -3.07M (+223.16%) | -950.00K (+1483.33%) | -60.00K (-57.14%) | -140.00K (-6.67%) | -150.00K (+66.67%) | -90.00K (+125.00%) | -40.00K (-50.00%) | -80.00K |
Net Income | -3.15M (+2.61%) | -3.07M (+223.16%) | -950.00K (+1483.33%) | -60.00K (-57.14%) | -140.00K (-6.67%) | -150.00K (+66.67%) | -90.00K (+125.00%) | -40.00K (-50.00%) | -80.00K |